A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies

por Iasonos, Alexia, Wilton, Andrew S, Riedel, Elyn R, Seshan, Venkatraman E, Spriggs, David R
Publicado 2008

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer

por Koneru, Mythili, O’Cearbhaill, Roisin, Pendharkar, Swati, Spriggs, David R, Brentjens, Renier J
Publicado 2015

Galectins and Ovarian Cancer

por Shimada, Chisa, Xu, Rui, Al-Alem, Linah, Stasenko, Marina, Spriggs, David R., Rueda, Bo R.
Publicado 2020

The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells

por Bellio, Chiara, DiGloria, Celeste, Spriggs, David R., Foster, Rosemary, Growdon, Whitfield B., Rueda, Bo R.
Publicado 2019

Time to publication of oncology trials and why some trials are never published

por Chapman, Paul B., Liu, Nathan J., Zhou, Qin, Iasonos, Alexia, Hanley, Sara, Bosl, George J., Spriggs, David R.
Publicado 2017

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials

por Hyman, David M., Eaton, Anne A., Gounder, Mrinal M., Pamer, Erika G., Pettiford, Jasmine, Carvajal, Richard D., Ivy, S. Percy, Iasonos, Alexia, Spriggs, David R.
Publicado 2015

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

por Wang-Gillam, Andrea, Tew, William P., Rothenberg, Mace L., Dupont, Jakob, Cooper, Wendy, Sternas, Lars, Buzenet, Giliane, Sosman, Jeffrey A., Spriggs, David R., Lockhart, Albert Craig
Publicado 2011

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies

por Stasenko, Marina, Smith, Evan, Yeku, Oladapo, Park, Kay J., Laster, Ian, Lee, Kwangkook, Walderich, Sven, Spriggs, Elizabeth, Rueda, Bo, Weigelt, Britta, Zamarin, Dmitriy, Rao, Thapi Dharma, Spriggs, David R.
Publicado 2021

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion

por Rao, Thapi D., Tian, Huasong, Ma, Xun, Yan, Xiujun, Thapi, Sahityasri, Schultz, Nikolaus, Rosales, Nestor, Monette, Sebastien, Wang, Amy, Hyman, David M., Levine, Douglas A., Solit, David, Spriggs, David R.
Publicado 2015

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

por O’Cearbhaill, Roisin E., Ragupathi, Govind, Zhu, Jianglong, Wan, Qian, Mironov, Svetlana, Yang, Guangbin, Spassova, Maria K., Iasonos, Alexia, Kravetz, Sara, Ouerfelli, Ouathek, Spriggs, David R., Danishefsky, Samuel J., Sabbatini, Paul J.
Publicado 2016

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

por Simon, George R., Ilaria, Robert L., Sovak, Mika A., Williams, Charles C., Haura, Eric B., Cleverly, Ann L., Sykes, Amanda K., Wagner, Margaret M., de Alwis, Dinesh P., Slapak, Christopher A., Miller, Mary A., Spriggs, David R.
Publicado 2011

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

por Yokota, Tomoya, Bendell, Johanna, LoRusso, Patricia, Tsushima, Takahiro, Desai, Ved, Kenmotsu, Hirotsugu, Watanabe, Junichiro, Ono, Akira, Murugesan, Bhavani, Silva, Joseph, Naito, Tateaki, Greenberg, Jonathan, Kumar, Prasanna, Wang, Yibin, Jikoh, Takahiro, Shiga, Ryota, Hyman, David M., Ho, Alan Loh, Spriggs, David R., Schwartz, Gary K., Gounder, Mrinal M.
Publicado 2018